4 Health Care Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.4%) at 15,601 as of Monday, Aug. 5, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,233 issues advancing vs. 1,686 declining with 120 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is down 0.2%. Top gainers within the sector include WellPoint ( WLP), up 2.4%, HCA Holdings ( HCA), up 1.8%, Illumina ( ILMN), up 1.5%, UnitedHealth Group ( UNH), up 1.3% and Aetna ( AET), up 1.2%. On the negative front, top decliners within the sector include Valeant Pharmaceuticals International ( VRX), down 1.6%, Vertex Pharmaceuticals ( VRTX), down 1.2%, Shire ( SHPG), down 1.2%, Agilent Technologies ( A), down 1.1% and AstraZeneca ( AZN), down 1.0%.

TheStreet would like to highlight 4 stocks pushing the sector higher today:

4. Alkermes ( ALKS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alkermes is up $1.26 (3.8%) to $34.89 on average volume. Thus far, 1.0 million shares of Alkermes exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $33.63-$35.58 after having opened the day at $33.85 as compared to the previous trading day's close of $33.63.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $4.6 billion and is part of the drugs industry. Shares are up 81.9% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Alkermes Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round